Why was Pfizer dismissed from the U.S. states' generic drug price-fixing lawsuit?

Chief Judge Michael Shea dismissed Pfizer because the states failed to show that Pfizer or its former unit Greenstone conspired with rivals between 2010 and 2014 to rig bids or allocate customers for six generic drugs—including Eplerenone, Latanoprost, and four Clindamycin phosphate versions—and ruled no reasonable jury could find Pfizer directly conspired, knew of Greenstone’s alleged collusion when approving price changes, or was liable under agency theory, noting Greenstone operated for profit beyond merely acting on Pfizer’s behalf.

What was the scope of the antitrust lawsuit from which Pfizer was dismissed?

The lawsuit was brought by 45 U.S. states, the District of Columbia, and four U.S. territories against 36 defendants, accusing them of conspiring to fix prices of 80 generic drugs—primarily for skin ailments—with allegations focused on coordinated activity involving Greenstone and Sandoz, including over 360 phone calls and text messages related to six specific drug products.

Pfizer Dismissed from US States' Drug Price-Fixing Lawsuit

Jun 24, 2026

A federal judge dismissed Pfizer from a multi-state antitrust lawsuit alleging generic drug price-fixing involving its former Greenstone unit, citing insufficient evidence of conspiracy between 2010 and 2014.

reuters

2026-05-05

Pfizer pins post 2028 return to growth on new obesity and cancer drugs

2026-06-24

Pfizer Dismissed from US States' Drug Price-Fixing Lawsuit

2026-08-04

Morning Bid: Earnings Overload

2026-08-28

13 Clinical Drug Candidates Unveiled at ACS Fall 2026 Meeting

Pfizer Dismissed from US States' Drug Price-Fixing Lawsuit

FAQ